Curasight A/S
Curasight A/S is a Danish clinical-stage radiopharmaceutical company developing a uPAR-targeted theranostics platform combining uTRACE® PET diagnostics and uTREAT® radioligand therapy to diagnose and treat aggressive solid tumors including glioblastoma, prostate, and other uPAR-expressing cancers.
- Company typePublic
- Founded2020
- HeadquartersCopenhagen, Denmark
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Curasight A/S does
Curasight A/S is a Danish clinical-stage radiopharmaceutical company developing a theranostics platform centered on the urokinase-type plasminogen activator receptor (uPAR), a protein expressed in more than 85% of solid tumors and implicated in tumor invasion, angiogenesis, and metastasis. Its two lead assets share the proprietary AE105 targeting ligand: uTRACE®, a uPAR-PET diagnostic imaging agent evaluated in more than 450 patients across nine Phase II trials in eight solid tumor indications, and uTREAT®, a first-in-class uPAR-targeted radioligand therapy administered via super-selective intra-arterial catheter injection with mannitol blood-brain barrier opening in brain indications. Lead clinical programs are a Phase 1 trial in glioblastoma (first patient dosed December 2025 with encouraging preliminary safety and uptake data) and a Phase 2 prostate cancer imaging trial run with Curium Inc. under an exclusive global license signed May 2023.
The company's business model is pre-commercial and license-driven. Curasight has no marketed products; future revenue is expected from product sales and licensing royalties following regulatory approval, with the Curium partnership serving as the template for asset-light commercialization in non-core indications. The company is listed on Spotlight Stock Market (ticker: CURAS) since October 2020, headquartered in Copenhagen with approximately 10 employees supplemented by specialist consultants, and has raised approximately DKK 97M at IPO plus DKK 51.2M via 2024 rights issue and additional directed issues and a DKK 40M Fenja Capital loan facility through 2025–2026. Operating losses have widened as expected (kDKK -55,592 in 2025 vs. -40,367 in 2024) reflecting clinical-stage R&D burn.
Curasight's strategic positioning rests on patent protection in Europe, US, Canada, and Japan (with the core US uTRACE® patent extended to 2035), a decade-plus academic foundation at Rigshospitalet and University of Copenhagen led by co-founder/CSO Professor Andreas Kjær, and a 'pipeline-in-a-drug' thesis that a single shared ligand can address multiple high-unmet-need solid tumors including glioblastoma, prostate cancer, neuroendocrine tumors, head and neck cancer, NSCLC, and pancreatic cancer.
Curasight A/S firmographics
Firmographics- Name
- Curasight A/S
- Legal name
- Curasight A/S
- Website
- https://curasight.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Curasight A/S is a Danish clinical-stage radiopharmaceutical company developing a uPAR-targeted theranostics platform combining uTRACE® PET diagnostics and uTREAT® radioligand therapy to diagnose and treat aggressive solid tumors including glioblastoma, prostate, and other uPAR-expressing cancers.
- Ownership category
- akta.pro rank
Curasight A/S industry classification
Industry- Product category
- Radiopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
Keywords
Where Curasight A/S is headquartered
LocationHeadquarters
- HQ city
- Copenhagen
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
Curasight A/S business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pre-commercial / Clinical-stage: Curasight is a clinical-stage radiopharmaceutical company with no marketed products. Revenue will be derived from product sales and/or licensing royalties following regulatory approval. The company has not yet disclosed commercial revenue.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Curasight A/S product offering
Product offeringCore offering
Curasight A/S is a clinical-stage Danish biotech company developing a proprietary uPAR-targeted theranostics platform. Its lead therapeutic candidate, uTREAT®, is a first-in-class radioligand therapy targeting aggressive solid tumors, paired with uTRACE®, a companion uPAR-PET imaging agent that enables patient selection and treatment monitoring. Both products share the same proprietary AE105 ligand targeting the urokinase-type plasminogen activator receptor (uPAR), which is expressed in more than 85% of solid tumors.
Product overview
Curasight A/S has developed a uPAR Theranostics Platform that combines two core products: uTRACE® (a uPAR-PET diagnostic imaging agent) and uTREAT® (a first-in-class uPAR-targeted radioligand therapy). Both products share the same proprietary uPAR-targeting ligand (AE105 peptide), enabling a true theranostic approach where uTRACE® is used for patient selection and tumor targeting confirmation, while uTREAT® delivers targeted radiation therapy. The platform is designed to treat aggressive solid tumors across multiple indications including glioblastoma, prostate cancer, neuroendocrine tumors, head and neck cancer, NSCLC, and pancreatic cancer.
Differentiator
Problem solved
Functional benefit
Brands
- uTRACE: uPAR-PET imaging and diagnostics technology for finding, visualising, and predicting whether a cancer is aggressive and how it should be treated.
- uTREAT
Products and services
- uTREAT® First-in-class uPAR-targeted radioligand therapy (RLT) designed to treat aggressive solid tumors including glioblastoma. It uses a proprietary ligand (AE105) to target the urokinase-type plasminogen activator receptor (uPAR), delivering targeted radiation directly to cancer cells while minimizing irradiation of healthy tissue. Intended for oncology patients with uPAR-expressing tumors.
- uTRACE®
Quantifiable outcome
- Phase 1 glioblastoma trial: clear and sustained uTREAT® uptake in tumor for at least 24 hours in first patient; biodistribution compatible with delivering therapeutically relevant radiation doses without reaching dose limits for healthy organs
- +2 more outcomes
Companies that use Curasight A/S
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Curasight A/S technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Curasight A/S partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Curium Inc.coreExclusive global license and collaboration agreement signed May 2023 with Curium Inc., a global leader in radiopharmaceuticals, for the development and commercialization of uTRACE® for use in prostate cancer. Curium supports Phase 2 prostate cancer trial across nine sites in Germany, Sweden, and Denmark. Part 1 of the trial is completed; Part 2 recruitment is well underway with completion expected in H1 2026.
- DLA Piper Denmark Law Firm P/SminorLegal advisor to Curasight, represented by Ulrik Bangsbo Hansen, Partner. Provides legal counsel for financing transactions, corporate governance, and regulatory matters. DLA Piper Denmark hosts Curasight's Annual General Meetings.
- Rigshospitalet / Copenhagen University Hospital / University of CopenhagencoreScientific foundation of uPAR platform originates from more than a decade of research at Rigshospitalet and University of Copenhagen, led by Professor Andreas Kjær and his research group. Research demonstrated uPAR expression in >85% of solid tumors including glioblastoma, pancreatic, prostate, lung, and colorectal cancers.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Curasight A/S competitors and assessment
Company assessmentBroad incumbents
- Bayer (Radiopharmaceuticals / Xofigo): Major pharma with approved radiopharmaceutical Xofigo (radium-223 for prostate cancer bone metastases) and active radioligand pipeline. Comparable as a large incumbent with overlapping radiopharma ambitions in solid tumor oncology.
- Lantheus Holdings: Radiopharmaceutical company with commercial imaging products (e.g., Pylarify for PSMA-PET imaging) and expanding radioligand therapy pipeline. Comparable to Curasight as a peer in nuclear medicine imaging and emerging therapy, though larger and commercial-stage.
- Novartis (Radioligand Therapy franchise): Acquired Pluvicto (177Lu-PSMA-617 for prostate cancer) and Lutathera (177Lu-DOTATATE for neuroendocrine tumors) — established the radioligand therapy category with FDA-approved products. Comparable as the dominant incumbent in the same therapeutic modality Curasight is pursuing, though Novartis has vastly greater resources and a commercial-stage product.
- POINT Biopharma (acquired by Eli Lilly): Clinical-stage radioligand therapy company (acquired by Lilly in 2023) developing next-generation radiopharmaceuticals targeting solid tumors including prostate cancer. Comparable platform strategy to Curasight, with strong validation of radiopharma M&A appetite.
- Bristol Myers Squibb (RayzeBio radiopharma acquisition): Acquired RayzeBio in 2024 to build an actinium-based radiopharmaceutical platform for solid tumors. Comparable as a large incumbent aggressively expanding into radioligand therapy, signaling strategic M&A interest in the category where Curasight operates.
- Fusion Pharmaceuticals (acquired by AstraZeneca): Clinical-stage radioconjugate company (now part of AstraZeneca) developing alpha-emitting radioligand therapies for solid tumors. Highly comparable platform approach to Curasight's uPAR-targeted radioligand, with the validation signal of a big-pharma acquisition.
Direct peers
- Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic radioligands (e.g., Illuccix for PSMA-PET imaging in prostate cancer). Most directly comparable to Curasight as a theranostic-focused radiopharma targeting solid tumors with both imaging and therapy agents.
- Curium Inc. Global leader in radiopharmaceuticals and Curasight's strategic partner under the exclusive global license for uTRACE® in prostate cancer. Highly comparable business model (radiopharma with diagnostic imaging products), though Curium operates at greater scale and commercial stage.
Emerging players
- ITM Isotope Technologies Munich SE: Radiopharmaceutical company developing targeted radionuclide therapies and diagnostics for solid tumors. Comparable as a clinical-to-commercial-stage radiopharma with theranostic ambitions in oncology.
- Clarity Pharmaceuticals: Clinical-stage radiopharmaceutical company developing both diagnostic (e.g., SAR-bisPSMA for prostate imaging) and therapeutic (SAR technology platform) agents. Closely comparable stage and theranostic approach to Curasight, also publicly listed with similar size profile.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Curasight A/S social profiles
Digital presenceCurasight A/S financial estimates
Financial estimateRevenue estimate
Valuation estimate
Curasight A/S leadership team
Management profileNumber of profiles
Profiles7 records
Curasight A/S funding detail
Funding detailFunding overview
Funding rounds7 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Curasight A/S M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Curasight A/S
What does Curasight A/S do?
Curasight A/S is a clinical-stage Danish biotech company developing a proprietary uPAR-targeted theranostics platform. Its lead therapeutic candidate, uTREAT®, is a first-in-class radioligand therapy targeting aggressive solid tumors, paired with uTRACE®, a companion uPAR-PET imaging agent that enables patient selection and treatment monitoring. Both products share the same proprietary AE105 ligand targeting the urokinase-type plasminogen activator receptor (uPAR), which is expressed in more than 85% of solid tumors.
Is Curasight A/S a public or private company?
Curasight A/S is a public company. It is classified as public and is currently operating.
When was Curasight A/S founded?
Curasight A/S was founded in 2020. It employs 1 to 10 people.
Where is Curasight A/S based?
Curasight A/S is headquartered in Copenhagen, Denmark, in the Europe region.
How does Curasight A/S make money?
One revenue line is on record: pre-commercial / Clinical-stage.
Who are Curasight A/S's main competitors?
Broad incumbents on record are Bayer (Radiopharmaceuticals / Xofigo), Lantheus Holdings, Novartis (Radioligand Therapy franchise), POINT Biopharma (acquired by Eli Lilly), Bristol Myers Squibb (RayzeBio radiopharma acquisition) and Fusion Pharmaceuticals (acquired by AstraZeneca). Direct peers are Telix Pharmaceuticals and Curium Inc.. Emerging players are ITM Isotope Technologies Munich SE and Clarity Pharmaceuticals.
Does Curasight A/S have an API?
No public API is recorded for Curasight A/S.
What industry is Curasight A/S in?
Curasight A/S's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx). Its NAICS code is 541714 and its SIC code is 2835.